Your browser doesn't support javascript.
loading
Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).
Sun, Hui-Chuan; Zhou, Jian; Wang, Zheng; Liu, Xiufeng; Xie, Qing; Jia, Weidong; Zhao, Ming; Bi, Xinyu; Li, Gong; Bai, Xueli; Ji, Yuan; Xu, Li; Zhu, Xiao-Dong; Bai, Dousheng; Chen, Yajin; Chen, Yongjun; Dai, Chaoliu; Guo, Rongping; Guo, Wenzhi; Hao, Chunyi; Huang, Tao; Huang, Zhiyong; Li, Deyu; Li, Gang; Li, Tao; Li, Xiangcheng; Li, Guangming; Liang, Xiao; Liu, Jingfeng; Liu, Fubao; Lu, Shichun; Lu, Zheng; Lv, Weifu; Mao, Yilei; Shao, Guoliang; Shi, Yinghong; Song, Tianqiang; Tan, Guang; Tang, Yunqiang; Tao, Kaishan; Wan, Chidan; Wang, Guangyi; Wang, Lu; Wang, Shunxiang; Wen, Tianfu; Xing, Baocai; Xiang, Bangde; Yan, Sheng; Yang, Dinghua; Yin, Guowen.
Afiliación
  • Sun HC; Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Zhou J; Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Wang Z; Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Liu X; Department of Medical Oncology of PLA Cancer Center, Jinling Hospital, Nanjing, China.
  • Xie Q; Department of Infectious Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Jia W; Department of Liver Surgery, The First Affiliated Hospital of USTC, Hefei, China.
  • Zhao M; Minimally Invasive Interventional Division, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Bi X; Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Li G; Department of Radiation Oncology, Beijing Tsinghua Changgung Hospital, Beijing, China.
  • Bai X; Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • Ji Y; Department of Pathology, Fudan University Shanghai Cancer Centre, Shanghai, China.
  • Xu L; Department of Liver Surgery, Sun Yat-sen University Cancer Centre, Guangzhou, China.
  • Zhu XD; Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Bai D; Department of Hepatobiliary Surgery, Clinical Medical College, Yangzhou University, Yangzhou, China.
  • Chen Y; Department of Hepatobiliopancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Chen Y; Division of Hepatobiliary Surgery, Department of General Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Dai C; Department of Hepatobiliary and Splenic Surgery, Shengjing Hospital Affiliated to China Medical University, Shenyang, China.
  • Guo R; The Department of Hepatobiliary Oncology of Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Guo W; Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Hao C; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Sarcoma Center, Peking University Cancer Hospital and Institute, Beijing, China.
  • Huang T; Department of Hepatobiliary Surgery, Affiliated Tumour Hospital of Zhengzhou University, Zhengzhou, China.
  • Huang Z; Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Li D; Department of Hepato-Biliary Pancreatic Surgery, Henan Provincial People's Hospital, Zhengzhou, China.
  • Li G; Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital, Naval Military Medical University (Second Military Medical University), Shanghai, China.
  • Li T; Department of general surgery, Qilu Hospital, Shandong University, Jinan, China.
  • Li X; Department of Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Li G; Center of General Surgery, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
  • Liang X; Department of General Surgery, Zhejiang University, School of Medicine, Sir Run Run Shaw Hospital, Hangzhou, China.
  • Liu J; The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
  • Liu F; Division of General Surgery, First Affiliated Hospital, Anhui Medical University, Hefei, China.
  • Lu S; Department of Hepatobiliary Surgery, First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
  • Lu Z; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Bengbu Medical College Bengbu, China.
  • Lv W; Department of Interventional Radiology, The Anhui Provincial Hospital, Hefei, China.
  • Mao Y; Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences (CAMS), Beijing, China.
  • Shao G; Department of Intervention, Zhejiang Cancer Hospital, Hangzhou, China.
  • Shi Y; Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Song T; Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China.
  • Tan G; Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
  • Tang Y; Department of Hepatobiliary Surgery, First Affiliated Hospital of Dalian Medical University, Dalian, China.
  • Tao K; Department of Hepatic-Biliary Surgery, The Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, China.
  • Wan C; Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
  • Wang G; Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wang L; Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, China.
  • Wang S; Liver Surgery Department, Shanghai Cancer Center, Fudan University, Shanghai, China.
  • Wen T; Department of Hepatobiliary Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Xing B; Department of Liver Surgery & Liver Transplantation Centre, West China Hospital of Sichuan University, Chengdu, China.
  • Xiang B; Hepatopancreatobiliary Surgery Department I, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China.
  • Yan S; Hepatobiliary Surgery Department, Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Key Laboratory for High-Incidence Tumor Prevention and Treatment, Ministry of Education, Guangxi Medical University Cancer Hospital, Nanning, China.
  • Yang D; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • Yin G; Unit of Hepatobiliary Surgery, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Hepatobiliary Surg Nutr ; 11(2): 227-252, 2022 Apr.
Article en En | MEDLINE | ID: mdl-35464283
Recent advances in systemic and locoregional treatments for patients with unresectable or advanced hepatocellular carcinoma (HCC) have resulted in improved response rates. This has provided an opportunity for selected patients with initially unresectable HCC to achieve adequate tumor downstaging to undergo surgical resection, a 'conversion therapy' strategy. However, conversion therapy is a new approach to the treatment of HCC and its practice and treatment protocols are still being developed. Review the evidence for conversion therapy in HCC and develop consensus statements to guide clinical practice. Evidence review: Many research centers in China have accumulated significant experience implementing HCC conversion therapy. Preliminary findings and data have shown that conversion therapy represents an important strategy to maximize the survival of selected patients with intermediate stage to advanced HCC; however, there are still many urgent clinical and scientific challenges for this therapeutic strategy and its related fields. In order to summarize and learn from past experience and review current challenges, the Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma (2021 Edition) was developed based on a review of preliminary experience and clinical data from Chinese and non-Chinese studies in this field and combined with recommendations for clinical practice. Sixteen consensus statements on the implementation of conversion therapy for HCC were developed. The statements generated in this review are based on a review of clinical evidence and real clinical experience and will help guide future progress in conversion therapy for patients with HCC.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Systematic_reviews Idioma: En Revista: Hepatobiliary Surg Nutr Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Systematic_reviews Idioma: En Revista: Hepatobiliary Surg Nutr Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: China